Cargando…
Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy
Canakinumab is a fully human monoclonal antibody that specifically neutralizes human interleukin (IL)-1β and has been approved by the US Food and Drug Administration for treating different types of autoinflammatory disorders such as cryopyrin-associated periodic syndrome, tumor necrosis factor recep...
Autores principales: | Lin, Wen-Wei, Lu, Yun-Chi, Huang, Bo-Cheng, Chuang, Chih-Hung, Cheng, Yi-An, Chen, I.-Ju, Liu, Hui-Ju, Ho, Kai-Wen, Liao, Tzu-Yi, Liu, En-Shuo, Wu, Ting-Yi, Chang, Long-Sen, Hong, Shih-Ting, Cheng, Tian-Lu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295355/ https://www.ncbi.nlm.nih.gov/pubmed/34290297 http://dx.doi.org/10.1038/s41598-021-94298-y |
Ejemplares similares
-
Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies
por: Huang, Bo-Cheng, et al.
Publicado: (2021) -
Correction: Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies
por: Huang, Bo-Cheng, et al.
Publicado: (2021) -
Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains
por: Chen, I-Ju, et al.
Publicado: (2017) -
Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy
por: Lu, Yun-Chi, et al.
Publicado: (2019) -
Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer
por: Cheng, Yi-An, et al.
Publicado: (2020)